Value of Emerging Agents in HER2+ mBC

EP: 1.Progression of HER2+ mBC

EP: 2.HER2+ mBC: Diagnosing Patients With Brain Mets

EP: 3.Monitoring Brain Mets in HER2+ mBC

EP: 4.Healthcare Utilization for HER2+ mBC With Brain Mets

EP: 5.Treatment Beyond Second-line Therapy in HER2+ mBC

EP: 6.Managing At-Risk Patients for Brain Mets in HER2+ mBC

EP: 7.HER2CLIMB Study

EP: 8.Phase 2 LANDSCAPE Trial

EP: 9.Phase 3 NALA Study

EP: 10.Phase 2 DESTINY-Breast01 Trial

Now Viewing

EP: 11.Value of Emerging Agents in HER2+ mBC

EP: 12.Sequencing HER2-targeted Agents in mBC

EP: 13.Approaching At-Risk Patients for Brain Mets in HER2+ mBC

EP: 14.Impact of Early Identification of Brain Mets

EP: 15.Patient-Centered Care for Treatment of Brain Mets

EP: 16.Payer Perspective: Impact of COVID-19 on Treatment of mBC

EP: 17.Impact of COVID-19 and Future of mBC Treatment

Bhavesh Shah, RPh, BCOP: As a payer and a provider, some of the values that are driven by these types of therapies are the reduction in distant metastases, CNS [central nervous system] relapse, and of course improvement in quality of life. We know that these patients have many symptoms, such as seizures and an increase in intracranial pressure, VTE [venous thromboembolism] risk, and neurocognitive decline. Having any type of improvement in many of these aspects is important and valuable to have. We’ll probably see it, especially with many of these new agents that have responses directly in the CNS. Having this longer CNS time to progression could also help with mitigating some of the adverse effects that these patients will have or those that would require intervention such as whole-brain radiation. We know that breast cancer is going to present with numerous brain metastases lesions that would ultimately require whole-brain radiation. If you can prevent whole-brain radiation, that is a value-driven outcome for any patient with this disease.